Summary
Elevance Health, Inc. (ELV) announced the successful closing of a significant notes offering on February 8, 2023, raising approximately $2.57 billion in net proceeds. This offering comprises three tranches of senior unsecured notes: $500 million of 4.900% Notes due 2026, $1 billion of 4.750% Notes due 2033, and $1.1 billion of 5.125% Notes due 2053. The company intends to use these proceeds for general corporate purposes, including funding potential acquisitions, repaying existing debt, and repurchasing its common stock. This capital raise provides Elevance Health with substantial financial flexibility. Investors should note the diverse maturity dates of the notes, offering a range of durations for fixed-income exposure. The proceeds' intended use suggests strategic initiatives, including potential M&A activity and shareholder return programs, which could be key drivers of future company growth and valuation.
Key Highlights
- 1Closed offering of $2.6 billion in aggregate principal amount of senior notes across three maturities (2026, 2033, 2053).
- 2Net proceeds of approximately $2.57 billion received after underwriting discounts and expenses.
- 3Intended use of proceeds includes working capital, general corporate purposes, funding acquisitions, debt repayment, and share repurchases.
- 4The 2026 Notes carry a coupon of 4.900%, the 2033 Notes at 4.750%, and the 2053 Notes at 5.125%.
- 5The Indenture does not place restrictions on the incurrence of additional indebtedness by the Company or its subsidiaries.
- 6Notes are subject to redemption at the Company's option under specific terms and conditions, including potential "Par Call" provisions.
- 7A change of control event coupled with a credit rating downgrade below investment grade could trigger a mandatory offer to repurchase the notes at 101% of principal.